The December 2024 FDA approval of Ryoncil for steroid-refractory acute graft-versus-host disease was not an orthopedic milestone. It was an immune milestone, confirming that the FDA will approve mesenchymal stem cell-based therapies for immune and inflammatory conditions when the Phase 3 evidence supports them. Ryoncil is a bone marrow-derived product, and its approval says nothing about any adipose-derived product. Early research suggests adipose-derived stem cells have immunomodulatory properties of the same general class, and researchers are studying ADSCs in registered clinical trials for Crohn’s disease, multiple sclerosis, lupus, rheumatoid arthritis, and other inflammatory conditions. Results are not final, and no adipose-derived product is FDA-approved for these conditions. This post reviews the biological mechanism, the published evidence, and the active trial pipeline for autoimmune and inflammatory applications of ADSCs, and explains what it means for patients with these conditions who are evaluating banking or trial enrollment.
TLDR: MSC immunomodulation is the mechanism behind the first-ever FDA-approved MSC product (Ryoncil, December 2024, for graft-versus-host disease). ADSCs share these properties. Active clinical trials are investigating ADSCs in Crohn’s disease, multiple sclerosis, lupus, rheumatoid arthritis, and other immune conditions. The evidence base is earlier-stage than orthopedics but growing rapidly. Banking does not provide access to a trial or to any future therapy. Patients with autoimmune conditions who are considering banking should discuss timing with their treating physician.
Important Disclaimer: Save My Fat does not provide FDA-approved treatments or cures for any disease, including Crohn’s disease, multiple sclerosis, lupus, rheumatoid arthritis, or any other autoimmune or inflammatory condition. No ADSC-based therapy for these conditions has received FDA approval as of the date of this post. Banking adipose tissue does not guarantee eligibility, access, or clinical benefit from any future therapy, clinical trial, or medical program. The clinical evidence described in this post is from published research and active trials, describing what is being investigated rather than what is proven or approved. All content is for educational purposes only and does not constitute medical advice. Consult your physician before making any healthcare decision.
The December 2024 FDA approval of Ryoncil changed the conversation about MSC-based therapies for immune conditions. Ryoncil is remestemcel-L-rknd, a bone-marrow-derived mesenchymal stem cell product approved for steroid-refractory acute graft-versus-host disease in pediatric patients after a completed Phase 3 randomized trial. It was not approved because MSCs are generally effective for all immune conditions. It was approved because a specific product, in a specific condition, with a specific patient population, completed the Phase 3 evidence standard the FDA requires. That is the same pathway that ADSC-based autoimmune trials are working toward.
For a patient with Crohn’s disease, multiple sclerosis, lupus, or rheumatoid arthritis who has been watching stem cell research for years, the Ryoncil approval shows that the FDA will approve an MSC product once that specific product completes Phase 3 in a specific condition. It does not show that the same approach works in these conditions. Early research suggests MSC immunomodulation may dampen the dysregulated immune responses and inflammatory signaling involved in these diseases, but the findings are preliminary. Ryoncil is a bone marrow-derived product, and its approval does not establish that adipose-derived cells work in any autoimmune condition. Only ADSC-specific trials in these conditions can answer that question, and results are not final.
This post covers the immunomodulatory mechanism, the condition-by-condition evidence base, the active trial pipeline, and the specific banking implications for patients with autoimmune conditions.
The Immunomodulatory Mechanism
How ADSCs Modulate the Immune System
Mesenchymal stem cells, including adipose-derived MSCs, exert immunomodulatory effects through four overlapping mechanisms:
- Direct suppression of T-cell and B-cell proliferation. MSCs secrete IDO (indoleamine 2,3-dioxygenase), TGF-beta, and PGE2, which inhibit the proliferation and activation of autoreactive lymphocytes.
- Promotion of regulatory T-cell differentiation. MSCs shift the T-cell balance toward regulatory T cells, which suppress pathological immune responses and help restore immune tolerance.
- Suppression of natural killer cell cytotoxicity. MSCs reduce NK cell activity, which contributes to the broader anti-inflammatory environment at the site of immune dysregulation.
- Macrophage polarization from the M1 pro-inflammatory phenotype to the M2 anti-inflammatory phenotype. This is a key mechanism in chronic inflammatory diseases where persistent M1 macrophage activity drives ongoing tissue damage.
The 2018 MSC clinical review from Galipeau and Sensebe in Cell Stem Cell, the 2019 MSC biology review from Pittenger and colleagues in npj Regenerative Medicine, and the 2006 ISCT minimal criteria from Dominici and colleagues together establish the biological framework these four mechanisms operate within. Save My Fat’s comparison of mesenchymal stem cells across sources puts the ADSC-specific immunomodulatory profile in context against the broader MSC category.
Why ADSCs Are Particularly Well-Suited
ADSCs produce anti-inflammatory secretory factors including HGF, IL-10, and TGF-beta at levels that compare favorably to bone-marrow-derived MSCs in some published comparisons. They are also more accessible. A gram of fat yields roughly 100 to 500 times more mesenchymal stem cells than a gram of bone marrow (Fraser et al., 2006), building on the foundational 2002 Zuk paper that identified adipose tissue as a stem cell source. This yield advantage makes autologous cell banking from adipose tissue more practical than bone marrow harvest for most patients, and the 2013 IFATS and ISCT joint consensus describes the characterization framework used to ensure adipose-derived cells meet the biological criteria the MSC category requires. Save My Fat’s patient-facing introduction to adipose-derived stem cells covers the practical implications of this yield advantage.
The FDA Approval That Changed the Benchmark
Ryoncil: The First MSC Approval
In December 2024, the FDA approved Ryoncil for steroid-refractory acute graft-versus-host disease in pediatric patients two months of age and older. This was the first approval of any MSC-based biologic product by the FDA, and it followed a Phase 3 randomized controlled trial that demonstrated an improvement in overall response rate at Day 28 versus comparator, documented in the FDA’s approved cellular and gene therapy products database.
What the Ryoncil Approval Does and Does Not Establish
The approval establishes one thing: the FDA will approve an MSC-based product for an immune condition when that product’s Phase 3 evidence meets the regulatory standard. It does not establish that adipose-derived cells work in any autoimmune condition. The FDA approves products, not mechanisms, and Ryoncil is a bone marrow-derived product. Early laboratory research suggests adipose-derived mesenchymal stem cells share some immunomodulatory properties with bone marrow MSCs, including effects on T cells and macrophages, but these findings are preliminary, and results do not transfer between sources.
ADSC autoimmune trials have to meet that evidence standard on their own, product by product and condition by condition. The 2018 MSC immunomodulation review covers MSC immunomodulation research and the broader autoimmune application landscape.
Condition-by-Condition Evidence Review
Crohn’s Disease and Inflammatory Bowel Disease
Crohn’s disease has the most mature MSC evidence base of any autoimmune condition, driven in part by the use of allogeneic MSCs in perianal fistula, a specific Crohn’s complication, which led to the European approval of Alofisel (darvadstrocel) in 2018, an authorization withdrawn in December 2024 after the confirmatory ADMIRE-CD II trial did not meet its endpoint. For systemic Crohn’s and IBD more broadly, ADSC and MSC trials have reported reductions in disease activity indices and evidence of mucosal healing in Phase 1 and Phase 2 studies. The active Crohn’s trial pipeline on ClinicalTrials.gov spans multiple indications and cell sources, and Save My Fat’s overview of ADSC autoimmune and inflammatory research covers the indication landscape in more depth.
Multiple Sclerosis
MSC trials in multiple sclerosis have progressed through Phase 1 and Phase 2, with published data describing reductions in relapse rates, MRI lesion activity stabilization, and improvements in disability measures in relapsing-remitting MS patients. The 2019 MSC biology review covers the mechanistic basis for why immunomodulation matters in MS specifically, and the active multiple sclerosis MSC trial pipeline lists current recruiting studies.
For MS patients asking about banking, researchers have raised a question about cell quality. Disease-related immune dysregulation and the systemic inflammation of active MS can affect autologous cell quality over time, and the 2018 MSC clinical review discusses this concern within the broader context of MSC therapy in chronic inflammatory disease. Researchers are studying adipose-derived cells for multiple sclerosis in registered clinical trials. Results are not final, no adipose-derived product is FDA-approved for multiple sclerosis, and banking does not provide access to a trial.
Systemic Lupus Erythematosus
ADSC and MSC trials in systemic lupus erythematosus have reported reductions in disease activity scores, reductions in anti-dsDNA antibodies, and improvements in complement levels in Phase 1 and Phase 2 studies. The active lupus MSC trial pipeline covers multiple investigational approaches, and the 2018 MSC clinical review situates the lupus evidence base within the broader autoimmune category.
Rheumatoid Arthritis
Rheumatoid arthritis represents a natural intersection of the orthopedic and autoimmune evidence arcs, a joint disease driven by immune dysregulation. ADSC and MSC trials in rheumatoid arthritis have reported reductions in DAS28 disease activity scores, reductions in synovial inflammation markers, and favorable safety profiles in early-phase trials. The active adipose mesenchymal autoimmune trial pipeline on ClinicalTrials.gov includes rheumatoid arthritis among the recruiting studies, and the 2019 MSC biology review describes the mechanistic rationale in physician-appropriate depth.
Graft-Versus-Host Disease
This is the condition for which MSC therapy has the highest level of evidence and the first FDA approval. The approval of Ryoncil for steroid-refractory acute graft-versus-host disease, listed in the FDA approved products database, establishes the proof of concept for MSC-based immune therapy. Autologous ADSC banking in the context of graft-versus-host disease is less directly applicable than allogeneic therapy, because graft-versus-host disease itself is a complication of allogeneic stem cell transplant. What the approval provides for the broader autoimmune category is mechanism validation, not product substitution, and the 2018 MSC clinical review covers how the graft-versus-host disease evidence base supports the broader immune application landscape.
The Active Trial Pipeline
Active clinical trials investigating ADSC and MSC therapies for autoimmune and inflammatory conditions are recruiting now. The pipeline spans inflammatory bowel disease, multiple sclerosis, lupus, rheumatoid arthritis, and other immune conditions, and the searches across these indications together give patients and physicians a view of the current investigational landscape. The adipose mesenchymal autoimmune search covers the broad autoimmune category. Condition-specific searches including the Crohn’s MSC pipeline, the multiple sclerosis MSC pipeline, and the lupus MSC pipeline provide condition-focused detail. Save My Fat’s resources on finding legitimate clinical trials and what ClinicalTrials.gov phases mean help patients and physicians interpret what they find in the registry.
Banking Implications for Autoimmune Patients
Timing Questions for Autoimmune Patients
For autoimmune patients, timing questions about banking are best discussed with the treating physician. Active disease, systemic inflammation, immunosuppressive medication, and disease-related oxidative stress may all affect ADSC biological quality over time. The cells banked during remission or early disease are typically higher quality than cells banked during active flares or after years of systemic inflammation, as the published MSC biology literature describes in its discussion of how cell function varies across health states. Save My Fat’s complete guide to banking covers the general timing rationale, and banking does not provide access to a trial or guarantee that banked cells will be usable for any autoimmune condition.
Autologous vs. Allogeneic: Why Banking Your Own Cells Matters
Most of the current ADSC autoimmune investigational protocols use autologous cells, meaning the patient’s own cells. Autologous cells do not raise the donor-matching concerns that allogeneic cells do, which is a meaningful consideration in patients whose immune systems are already dysregulated by their underlying condition. A patient who banks their own cells during relative health preserves the autologous starting material that autologous trial protocols and autologous expanded access pathways require, and the IFATS and ISCT joint consensus on adipose-derived cell characterization together with the 2018 MSC clinical review establish the biological rationale for why autologous sources matter in this context. Save My Fat’s overview of how banking works describes the banking process from the patient’s perspective.
Expanded Access as a Near-Term Pathway
For patients with serious autoimmune conditions who cannot wait for a trial or approval, expanded access is the formal FDA pathway for accessing investigational therapies. The Reagan-Udall Foundation’s Expanded Access Navigator is the recommended starting resource, and Save My Fat’s expanded access programs overview covers how banking relates to potential autologous ADSC expanded access requests. Expanded access is not a guaranteed pathway, but for patients with qualifying conditions who have exhausted standard options, it is worth evaluating alongside clinical trial enrollment and banking.
Evidence Summary Table
| Condition | Evidence Level | Key Signal | Active Trials |
|---|---|---|---|
| Graft-versus-host disease | Phase 3 RCT, FDA-approved (Ryoncil) | Day 28 response rate improvement | Limited, approval achieved |
| Crohn’s and perianal fistula | Phase 3 with EU approval (Alofisel, withdrawn December 2024), plus active ADSC trials | Fistula healing, disease activity reduction | Active recruiting |
| Multiple sclerosis | Phase 1 and 2 | Relapse rate reduction, MRI stabilization | Active recruiting |
| Systemic lupus | Phase 1 and 2 | SLEDAI reduction, antibody normalization | Active recruiting |
| Rheumatoid arthritis | Phase 1 and 2 | DAS28 reduction, synovial inflammation markers | Active recruiting |
The FDA approved products database, the 2018 MSC immunomodulation review, and the adipose mesenchymal autoimmune trial search together form the primary reference set for the evidence levels summarized in the table.
Frequently Asked Questions
Is Ryoncil an adipose-derived stem cell product?
No. Ryoncil is a bone-marrow-derived allogeneic MSC product manufactured by Mesoblast, approved by the FDA in December 2024 and listed in the FDA approved cellular and gene therapy products database. The relevance of its approval to ADSC autoimmune research is mechanistic rather than product-level. Adipose-derived mesenchymal stem cells are studied for immunomodulatory properties of the same general class, but Ryoncil is a bone marrow-derived product and its approval says nothing about any adipose-derived product. Source tissue shapes cell behavior, and results do not transfer between sources.
Should patients with active autoimmune disease bank their cells?
Banking during relative disease remission or early disease typically preserves better quality cells than banking during active inflammatory flares or after years of systemic immunosuppression, based on the published MSC biology literature describing how cell function varies with health state. The specific timing question is worth discussing with the treating physician, because the optimal window depends on disease severity, current medications, and projected disease trajectory. The general principle is that earlier banking preserves better options.
Can patients on immunosuppressive medications still bank?
This is a clinical question for the treating physician. Immunosuppressive medications primarily affect circulating immune cell populations, but the target cells for banking are adipose-derived stromal cells rather than circulating immune cells, and the direct impact of most immunosuppressive regimens on adipose-derived cell quality is not as clear-cut as the impact on circulating cells. A physician familiar with both the patient’s medication history and the banking protocol can advise on whether current medications affect harvest timing or cell characterization.
Are there active trials for my specific condition?
Active trials can be searched by condition on ClinicalTrials.gov. For autoimmune and inflammatory conditions specifically, the Crohn’s MSC trial search, the multiple sclerosis MSC trial search, and the lupus MSC trial search cover the three most commonly searched conditions. Save My Fat’s guide on finding legitimate clinical trials helps patients evaluate what they find in the registry.
What is the best first step for a patient with a serious autoimmune condition who wants to explore ADSC options?
Three parallel steps, all of which can be pursued in the same week rather than sequentially. First, search ClinicalTrials.gov for active recruiting trials in the specific condition. Second, use the Reagan-Udall Navigator to evaluate whether expanded access might be relevant given the specific condition severity and available alternatives. Third, if banking is of interest, raise it with the treating physician, keeping in mind that banking does not provide access to a trial or to expanded access. These steps are not mutually exclusive, and the Save My Fat resource on expanded access programs covers the intersection of banking and the expanded access pathway in more depth.
Key Takeaways
The FDA approves products, not mechanisms. Ryoncil’s December 2024 approval for graft-versus-host disease showed that one MSC-based immune therapy can clear the full FDA pathway, but the approval applies only to that bone marrow-derived product and says nothing about any adipose-derived product.
ADSCs share the immunomodulatory properties that drive MSC efficacy in immune conditions. The four core mechanisms (IDO and TGF-beta and PGE2 suppression of lymphocyte proliferation, regulatory T-cell promotion, natural killer cell suppression, and macrophage polarization toward the anti-inflammatory phenotype) are present across the MSC category and form the biological basis for active ADSC autoimmune trials.
Active ADSC and MSC trials are recruiting for Crohn’s disease, multiple sclerosis, lupus, rheumatoid arthritis, and other autoimmune conditions. The evidence base for autoimmune applications is earlier-stage than orthopedics but moving through Phase 2 across multiple conditions simultaneously, which is the pattern that typically precedes Phase 3 pivotal trials in cell therapy.
For autoimmune patients, timing questions about banking belong with the treating physician. Published reviews suggest active disease and systemic inflammation may affect cell quality over time, but banking does not provide access to a trial, and no adipose-derived product is FDA-approved for any autoimmune condition.
Autologous cell banking avoids the donor-matching question that allogeneic tissue raises, which is a meaningful consideration for patients whose immune systems are already dysregulated. Most current autoimmune investigational protocols use autologous cells, and banking during relative health preserves the autologous starting material those protocols require.
Expanded access through the Reagan-Udall Navigator is available for patients with serious conditions who cannot wait for trial enrollment or approval. Banking, clinical trial enrollment, and expanded access are three parallel pathways that can be evaluated simultaneously rather than sequentially for patients with autoimmune conditions that are progressing faster than the research pipeline.
Next Steps for Patients and Providers
Before taking any next step: adipose tissue banking is a preservation service for potential future use in FDA-regulated pathways, not a treatment or a guarantee of access to any specific clinical trial, therapy, or product. No ADSC-based therapy for Crohn’s disease, multiple sclerosis, lupus, rheumatoid arthritis, or any other autoimmune condition is FDA-approved, and banking cannot be represented to patients as a treatment for these conditions. Physicians considering partnership should independently verify applicable state licensing and informed-consent requirements, particularly in Florida, Utah, California, Georgia, and Tennessee, which have stem cell-specific statutes.
For patients with autoimmune conditions, the Save My Fat overviews of how banking works, ADSC autoimmune and inflammatory research, and expanded access programs together provide the research framework for evaluating banking in the context of a specific autoimmune condition. The adipose mesenchymal autoimmune trial search and the Reagan-Udall Foundation’s Expanded Access Navigator cover the two alternative access pathways.
For providers in rheumatology, gastroenterology, neurology, and internal medicine, the Save My Fat provider program overview and the partner sign-up page are the starting resources for adding banking as a service line that fits a practice already seeing autoimmune patients.
Save My Fat works with a U.S.-based tissue bank for laboratory processing and storage. Save My Fat does not provide medical treatments, clinical trial enrollment, or Expanded Access services.
This article is for educational purposes only and does not constitute medical or legal advice. Please consult your own licensed healthcare provider before making any decisions about treatment or research participation.
About the author: Oscar Tellez is the founder and CEO of Save My Fat. He holds a Bachelor of Science in Exercise Science and Health Promotion from Florida Atlantic University. He has spent a decade in the regenerative medicine industry across product distribution, laboratory and vendor relationships, and provider training. He is not a licensed clinician, and this article is educational, not medical advice.
Related guide: the adipose stem cell clinical trials directory.
